Merck & Co. Reports Strong Cash Flow Amid Significant Profit Decline and Rising Costs

Merck & Co., Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in evaluation, reflecting changes in its financial metrics. The company reported its highest operating cash flow at USD 19,967 million, alongside a notable dividend per share of USD 5.07, indicating a strong cash generation capability. Additionally, the inventory turnover ratio reached 2.85 times, suggesting efficient inventory management. However, the company faced challenges in its quarterly performance for June 2026, with pre-tax profit declining to USD 893 million, a significant drop of 79.4%. Net profit also saw a substantial decrease, falling to USD 241 million, down 93.16%. The return on capital employed (ROCE) was recorded at 6.98%, which is lower than previous periods, while raw material costs increased by 5.55% year-over-year. Furthermore, cash and equivalents stood at USD 12,955 million, marking a low point for the company. Despite these challenges, Merck & Co., Inc. has demonstrated strong management efficiency and a solid ability to service its debt, with a low debt-to-EBITDA ratio of 1.58 times. The stock's recent evaluation adjustment reflects these mixed financial indicators. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.